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Abstract: The mechanisms of cell death can be predetermined (programmed) or not and 
categorized into apoptotic, autophagic and necrotic pathways. The process of Hayflick limits 
completes the execution of death-related mechanisms. Reactive oxygen species (ROS)  
are associated with oxidative stress and subsequent cytodamage by oxidizing and degrading 
cell components. ROS are also involved in immune responses, where they stabilize and 
activate both hypoxia-inducible factors and phagocytic effectors. ROS production and 
presence enhance cytodamage and photodynamic-induced cell death. Photodynamic cancer 
therapy (PDT) uses non-toxic chemotherapeutic agents, photosensitizer (PS), to initiate a 
light-dependent and ROS-related cell death. Phthalocyanines (PCs) are third generation and 
stable PSs with improved photochemical abilities. They are effective inducers of cell death 
in various neoplastic models. The metallated PCs localize in critical cellular organelles and 
are better inducers of cell death than other previous generation PSs as they favor mainly 
apoptotic cell death events. 









At the cellular level, death is a well-understood biological process and refers to the inability of  
a cell to preserve indispensable life functions. In mammalian cells, the process is important for both 
development and homeostasis [1]. Cell death assists life by removing damaged cells and superfluous 
cells that are capable of causing harm and, therefore, need to be destroyed for the advantage of the whole 
organism [2]. After suffering damages beyond repair and becoming inadequate for the entire organism, 
damaged cells undergo cell death mechanisms. For an individual to reach its post-embryonic maturity, 
superfluous cells, such as those in the interdigital spaces, are to be destroyed to prevent syndactyly [3]. 
An average individual loses half of his/her body mass annually, and without this process, the individual 
would have accumulated a bony mass of more than two tons and a 16 kilometer long intestine by the age 
of 80 [4]. 
1.1. Apoptosis 
Depending on cellular aspects such as morphology, enzymatic activity, functional and immunologic 
responses, the mode of cell death is determined and designated as either a programmed or non-programmed 
mode [5]. Nuclear and membrane degradation characterize apoptosis, which is the standard programmed 
and also the most occurring cell death [6]. It is triggered by precise signals that lead to the activation of 
cascade pathways to finally deliver a suicidal response. Therefore, apoptosis is an induced and regulated 
process that activates a family of proteins (known as caspase) and precise cellular events, which degrade 
nucleic and polypeptide materials. Caspases are cysteine aspartyl proteases and can further stimulate 
others effector agents to digest cellular contents. Additionally, the apoptotic response is enhanced  
upon the binding of BH3-only members of the Bcl-2 family to and inhibiting the action of  
pro-survival proteins. 
As a consequence, affected cells round up and cease communication with adjacent cells; their plasma 
membranes bleb, and phosphatidylserines translocate to the outer layers (Table 1). These mechanisms are 
accompanied by additional cellular changes, including cross-linkage and polymerization of proteins, 
chromatin condensation, nuclear fragmentation from ±300,000 to 185 nucleotides through internucleosomal 
degradation by cation-dependent endonuclease and, finally, cellular fragmentation into apoptotic bodies 
and removal. Permeable mitochondrial membranes and the release of apoptogenic substances, such as 
cytochrome C, characterize the intrinsic pathway, while the activation of death receptors, such as tumor 
necrosis factor receptor 1 (TNFR1) or Fas/CD95, on the plasma membrane characterizes the extrinsic 
pathway [3,6–8]. In contrast, the presence of Beclin 1 prevents caspase-dependent cell death events and 
demonstrates anti-apoptotic potential [8]. Silicon phthalocyanine (PC-4) photosensitizer (PS) was used 
in photodynamic therapy (PDT) to cause damage to CD4+ CD7− malignant T-lymphocytes. PC-4 was 
efficient at inducing cytodamage by destroying BCL-2 proteins and promoting apoptosis [9]. Similarly, 
a metallo-PC-mediated PDT in breast cancer cells led to apoptosis signs, including the predominance  
of apoptotic cells post-PDT; nuclear fragmentation was seen as oligonucleosomal degradation and 
increased expression of the B-cell lymphoma 2 (Bcl-2), DNA fragmentation factor alpha (DFFA1) and 
caspase 2 (CASP2) genes [10]. PSs that preferentially accumulate in mitochondria and damage BCL-2 
protein, like PC, generally are inducers of apoptosis [11]. Additionally, the level of calcium ions (Ca2+) 
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and the transfer from endoplasmic reticulum to mitochondria represent further criteria for cell death 
induction. The overload of Ca2+ in mitochondria leads to changes in morphology and apoptosis in  
a nonnuclear and Ca2+-dependent manner [12]. In the presence of an increased level of intracellular Ca2+, 
PDT has the ability to induce cytodamage, which also appears to be p53 dependent [13]. 
Table 1. Distinctive characteristics of cell death pathways. Different cell death pathways  
can be classified according to morphological appearance (apoptotic, autophagic, necrotic), 
enzymological criteria or regulators (distinctive classes of proteases, such as caspases, calpains 
and kinases) and functional aspects (programmed or accidental, physiological or pathological). 
Distinctive 
Features 
Cell Death Pathways 




DNA degradation;  
nuclear fragmentation,  
apoptotic bodies 
Decreased cell size;  
double membrane vesicles; 
organelle degradation 
Cell swelling; loss of  
membrane integrity; 
organelle swelling;  
NO DNA laddering 
Regulators 
Death receptors; Bcl-2 
family; Beclin 1; caspases; 
IAPs; adaptor proteins; 
kinases; phosphatases; 
calcium ions, calpains; 
BCNI1 
mTOR; PI3 kinase; ATG 
family; UPR stress sensors; 
Beclin 1; kinase (JNK);  
Bcl-2 family; IP3 receptor 
Calcium ions; ion channels; 
metabolic failure; PARB,  
calcium-regulated proteins; 
RIP kinase;  
death receptors; ceramides 
Stimuli 
ROS; DNA damage;  
death receptors ligands; 
developmental programs; 
organelle stress;  
anti-cancer drugs;  
ER calcium release 
Nutrient starvation; protein 
aggregation; ER stress; 
calcium overload; 
developmental programs; 
hypoxia; ischemia;  
damaged organelles; 
proteasome impairment 
bacterial toxins; metabolic 
poisons; ischemia; stroke; 
calcium overload 




Abbreviations: ATG, autophagy; Bcl-2, B-cell lymphoma 2; IAPs, inhibitor of apoptosis proteins;  
IP3 receptor, inositol 1,4,5-trisphosphate (IP3) receptors; ER, endoplasmic reticulum; mTOR, (mammalian)  
target of rapamycin; PAR, poly(ADP-ribose); NO, nitrite oxide; PARB, PAR-binding site; PI3 kinase, 
phosphatidylinositide 3-kinases; UPR, unfolded protein response; ROS, reactive oxygen species; RIP1, oxygen 
species; RIP1, a specific kinase that is recruited to the death-inducing signaling complex. 
1.2. Autophagy 
Embryological studies revealed that cells are accumulated and damaged in vesicles during a 
programmed cell death known as autophagy, an essential, but selective cell degrading process [14]. 
Autophagy is thought to be primarily a pro-surviving mechanism initiated by cells that have to face  
sub-lethal levels of damage [15]. Additionally, autophagy was shown to promote the induction of 
immunogenic cell death and to play a critical role in photodynamic-related cell damages, especially in 
apoptosis-resistant cells [16]. When inhibiting autophagic actions, cancer cells showed resistance  
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and increased cell survival after treatment [17]. Thirty autophagy-related genes (Atg) and two  
ubiquitin-dependent mechanisms have been identified, but Atg7 protein is involved in both mechanisms 
and participates in other Atg activations, autophagosomal assemblage and molecular degradation [18]. 
Unlike apoptosis, autophagy is not well understood, but has also been reported to be involved in either 
cell survival or death function [19]. 
Autophagy is a catabolic process comprised of reactive oxygen species (ROS) accumulation, 
membrane lipid oxidation on the membrane and loss of plasma membrane integrity in the absence of 
caspase activities. Caspase is a family of cysteine proteases that are inducers and effectors of changes 
occurring during apoptosis [3,20,21]. Caspase inhibition induces catalase degradation and ROS 
accumulation. The accumulation of ROS is dependent on the activity of catalase and is related to 
autophagy [22]. This mode of cell death has several roles in many biological pathways and differs from 
endocytosis lysosomal destruction by the formation of an autophagosome, which engulfs the target 
components to be degraded within the lysosomes [23]. Four consecutive steps make up this process, and 
these are: appropriation, transportation to lysosomes, degradation and reutilization of residues (Table 1). 
Lysosomes are the sites for cellular degradation and prompt cell death through the release of lysosomal 
hydrolases into the cytoplasm, prompting cell death. The action of autophagic proteins protects 
neighboring cells from the detrimental effects of lysosomal degradation [24]. A regulated autophagy 
controls the cell metabolism by degrading, recycling and synthesizing cell components [25,26]. PDT is 
recognized to activate apoptosis, but it can also induce autophagy in several types of cells, where the 
autophagic response can either involve survival or cell death mechanisms. Autophagy is first of all  
a survival mechanism, and autophagy-triggered PDT can add resistance to the therapy by inhibiting cell 
death signals. However, apoptosis-deficient cells depend on autophagic responses to induce cell death 
after PC-4 PDT. Both apoptosis and autophagy are required for an enhanced cell death response, and 
when blocking autophagy, MCF-7 cells develop resistance to PC-mediated PDT, resulting in increased 
cell survival [27,28]. PCs that localize in the endoplasmic reticulum and affect both the mammalian 
target of rapamycin (mTOR) activation and Beclin-1 protein are likely to lead to a comprehensively 
autophagic cell death response [11]. 
1.3. Necrosis 
Necrosis has been referred to as an accidental and non-programmed cell death event. There is an 
absence of signals associated with programmed cell death, and an inflammatory response characterizes 
this mode of death. External stimuli, such as infections, toxins and trauma, are required to initiate a 
necrotic cell death response [5,29]. In the absence of caspase activity in eukaryotic cells, it was shown 
that signal transduction and catabolic activities govern the execution of the necrotic pathway through the 
death domain and toll-like receptors. The activity of the receptor interacting protein (RIP1) controls the 
promotion of this cell death. RIP1 is a serine/threonine kinase required for the death receptor signaling 
and necroptosis, which is a necrotic-like and caspase-independent programmed cell death (Table 1) [30]. 
Seven types of necrotic cell death pathways have been recognized, but the sequential events  
remain unchanged for all. They include membrane permeability, movement of calcium ions across  
the endoplasmic reticulum, cytoplasmic swelling (oncosis), calcium-dependent calpain activation, 
lysosomal rupture, followed by degradation of cell components and induction of the inflammatory  
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response [31]. Though it lacks the distinctive characteristics of apoptosis and autophagy, necrosis is 
comprised of precise sequential events; therefore, it can occur in a controlled manner. The efficiency of 
the liposomal aluminum chloro-phthalocyanine (AlClPC) in PDT was studied both in vitro and in vivo 
using the oral cancer cell line Ehrlich tumor cells, and AlClPC-mediated PDT led to 90% necrotic cell 
death and disruption of blood vessels [32,33]. Another PC, zinc phthalocyanine tetra-sulfonated, was 
found to possess anti-neoplastic activity after PDT, and an evident increase of necrotic-related cell death 
was seen [34]. Subcellular localizations with cell membrane disintegration, local depletion of oxygen 
and nutrients are prone to receive PCs that would stimulate cell death by necrosis [11]. 
The relative uptake, cytodamage and subcellular localization are all dependent on distinctive chemical 
features of each PC. Neutral PCs showed more diffuse localization and were likely to primarily localize 
in the Golgi apparatus in the perinuclear area. Though both cationic and anionic PCs prefer lysosomes 
as their initial sites of localization, the cationic, followed by the neutral PCs appeared to be more 
effective than their anionic counters. Following irradiation, PCs undergo relocalization, which is charge 
dependent, and this demonstrated that the secondary localization site is more important in predicting the 
outcome of any PC-mediated PDT [35]. 
1.4. Reactive Oxygen Species and Photodynamic Cancer Therapy 
ROS have been considered only as a metabolic by-product and are intentionally produced by the Nox 
family NADPH oxidases on cell membranes during immune response. These phagocyte oxidases are 
crucial in innate immunity and are usually inactivated in resting cells. During phagocytosis, they are 
activated to produce ROS, which are the precursors of oxidants. This generation of ROS during 
phagocytosis makes Nox family NADPH oxidases major effectors in the protection mechanism [36,37]. 
In mitochondria, ROS stabilize hypoxia-inducible factors (HIF-1), which are a transcriptional regulator 
of the immune response and are essential for the secretion of tumor necrotic factor (TNF-alpha) [38]. 
The action of ROS on HIF-1 changes the mitochondrial functions and leads to the modulation of the 
immune response. This altered immune function can enhance lifetime [39]. Patients with dysfunctional 
oxidases suffer from improved vulnerability to microbial infection. ROS attack bacteria in the isolated 
neutrophil phagosomes. Nox family NADPH oxidases and ROS are important in innate immunity for 
the eradication of microbial infection [40]. 
Elevated levels of ROS, downregulation of ROS scavengers and antioxidant enzymes are associated 
with various human diseases, including diabetes, neurodegenerative diseases and various cancers. 
Cancer is a multistage disorder and a leading cause of death worldwide. The term cancer is characterized 
by the proliferation and invasion of abnormal cells without control in an organ. The abnormal cells  
can spread to other organs and body locations through the blood or lymph systems. Several types of 
cancer have been identified, and the most-commonly diagnosed include breast cancer, colorectal cancer, 
endometrial cancer, kidney cancer, lung cancer, cervical cancer, skin cancer, non-Hodgkin lymphoma, 
melanoma, leukemia, pancreatic cancer, prostate cancer and thyroid cancer [41,42]. Early diagnosis is 
critical for the efficiency of the treatment. Surgery, radiation therapy and chemotherapy are effectively 
used in the battle against cancer, but their lack of specificity for cancer cells causes damage to normal 
healthy cells, numerous side effects and loss of cell functions. Thus, there is an increasing interest to 
develop more sensible and effective discriminatory means of treating cancer [10,43]. 
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Photochemotherapy of cancer, also known as photodynamic therapy (PDT), is a sequential 
photochemical and photobiological process that aims to irreversibly target and damage malignant  
tissues [44]. This therapy is an evolving and clinically-approved approach that exerts selective cytotoxic 
activities on malignant cells. It involves the administration of a photosensitizer (PS), followed by local 
irradiation at a wavelength that matches the absorbance band of the PS used [45–47]. In the presence of 
oxygen, irradiation induces activation of PS and a series of reactions leading to the generation of  
singlet oxygen and free radicals, followed by cell death. The mechanisms of cell death include direct 
tumoricidal effects, microvascular damage and induction of potent local inflammatory responses and  
depend mainly on the type and dose of PS used, the intensity of irradiation and the level of oxygen 
(Figure 1) [48,49]. 
 
Figure 1. Photodynamic cancer therapy (PDT)-mediated cellular effects. Photosensitizer 
(PS) localizes in tumor cells and is converted from its ground to singlet state form through 
light activation. Singlet state PS can lose energy in form of heat or fluorescence, but an ideal 
photodynamic PS undergoes inter-system crossing and transforms into the triplet state  
form. Triplet state PSs with a long lifespan mediate reactive oxygen species (ROS) 
generation within cells. ROS induce cytotoxic effects (predominantly apoptotic and  
necrotic types of responses, with the exception of autophagy, which is more cytoprotecting 
than cytodamaging), causing cell damage and destruction. 
In both clinical and experimental setting, most PSs do not localize in nuclei, but rather in plasma 
membrane, lysosomes, mitochondria, endoplasmic reticulum (ER) and Golgi apparatus. PSs enter cells 
through the plasma membrane or by endocytosis, and this subcellular localization depends on the 
physico-chemical properties of PSs [50,51]. For optimal photodynamic actions and efficiency, the PSs 
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used should have an absorption peak between 600 and 800 nm, as at longer wavelengths than 800 nm, 
photons become inefficient and generate insufficient energy to excite oxygen to its singlet state  
and therefore yield insufficient ROS and cell damage. Light that penetrates into tissues is directly 
proportional to the wavelength. PSs with relatively strong absorbance in the red or near-infrared region 
of the electromagnetic spectrum are often preferred over the blue light-absorbing PSs, as blue light 
penetrates less effectively through tissues than red light [48]. Good PSs have limited dark toxicity and 
relatively rapid clearance from normal tissue, thus reducing phototoxic side effects. Photodynamic 
actions are sometimes associated with an acute inflammatory response characterized by an increased 
level of inflammatory cytokines and accumulation of leukocytes in targeted tumor areas, and  
PDT-mediated anti-tumor immunity has been reported [52,53]. All of these lead to an acute stress 
response that includes changes in the Ca2+ level, lipid metabolism, cytokine production and stress 
mediators [11]. In many photodynamic responses, the inductor stimulus is 1O2, originating from 
mitochondria, which enhances the formation of the receptor interacting protein 3 (RIP-3) complex. The 
cellular mechanism by which ROS generate such a response is not well understood [54,55]. 
Porphyrin had attracted the attention of photodynamic researchers and has good planar aromatic  
ring structures and photophysical properties with synthetic adaptability [56]. Due to the poor relative yield 
and limited efficiency in photodynamic applications, porphyrin is subjected to chemical modifications in 
order to improve its photochemical features and photodynamic therapeutic effectiveness, from the first 
generation into its second, then third generation. Phthalocyanine evolved from porphyrins and shares 
some of features of its precursors (Figure 2). Moreover, it is a better photodynamic agent with a higher 
yield and improved spectroscopic properties that are within the therapeutic window. Those synthetic 
modifications increase also the specificity of PC for neoplastic targets [53,57]. 
 
Figure 2. Synthesis of phthalocyanine (PC). The O-cyanobenzamide reacts with phthalimide 
to give a tetrabenzoporphyrin, also known as phthalocyanine. The structure of PC resembles 
that of the precursor porphyrin. PCs are tetradentate and capable of coordinating metal ions 
within their nitrogenous core. Chemical alternations are made possible at the metal center 
and substitutions at the benzo periphery (Portions 1–4, 8–11, 15–18 and 22–25). 
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Phthalocyanine-mediated PDT has been shown to enhance autophagy, caspase-3 activation and 
increased cell killing [58]. After their unintended discovery during the preparation of phthalimide from 
phthalic anhydride in 1928, phthalocyanines (PCs) and their derivatives have since attracted attention. 
Preliminary studies on these interesting compounds determined both their structures and names from 
their phthalic anhydride origin (phthalo) and deep blue coloration (cyanine). PCs are mostly red  
light-absorbing compounds and referred to as tetrabenzotetraazaporphyrins; macrocyclic structured 
compounds with isoindole and nitrogen atoms at their meso-positions [59]. These flexible and stable 
compounds have enhanced light absorbing abilities and have been used as chemical sensors, 
semiconductors, non-linear optics and photodynamic agents [60,61]. Several factors, including the 
degree of ligation, the nature of the central atom, the composition of the solvents, peripheral substitution, 
aggregation, as well as extension of conjugation, contribute to their absorbance in the optical 
transmission window of biological tissues [62]. In their naturally-occurring forms, the hydrophobic 
characteristics of their aromatic cores make them insoluble in most solvents, which ensures their 
durability when used as dyes. However, applications require functionalized PCs, and in order to increase 
the solubility in organic solvents and to reduce aggregation, different substituents are incorporated in the 
peripheries of PCs. 
Some porphyrin-related PSs accumulate in the vasculatures of tumor cells, and subsequent irradiation 
induces several damages, including stasis, vascular collapse and leakage; the mechanisms of action 
remain unknown [44]. Metallated PCs have been identified as strong inducers of cytodamage and 
preferentially accumulate in tumor cells, where they stimulate photodamages in various tumor models. 
In vitro, they have been associated with the induction of the apoptotic and necrotic pathways, while  
in vivo, PCs promote cell death through translocation of activated p38 to mitochondria, phosphorylation 
of BCL2 and/or BCL-X2, through facilitation of cytochrome C release from mitochondria,  
caspase-mediated PARP cleavage and inhibition of the P13/Akt/mTOR pathway [63,64]. Most PCs 
adhere to the following main features: low cytotoxicity in the dark, high phototoxicity upon light 
activation, high selectivity and specificity for targeted tumor, rapid clearance from the body, absorption 
in the optical transmission window of biological tissues, high quantum yield of singlet oxygen 
production, solubility in water-based solutions and stability under physiological conditions [65]. 
Metallated PC family members were used to investigate their phototherapeutic activities in various 
cancer cell lines. A mixed sulfonated metallophthalocyanine with zinc as the central atom (ZnPcSmix) 
successfully entered cells and localized in vital organelles, including mitochondria, lysosomes and Golgi 
apparatus. ZnPcSmix compounds had the ability to absorb light at a wavelength of 680 nm and showed 
photodynamic activities, neoplastic damage and good therapeutic results in lung, colon and breast cancer 
cells [66,67]. The effects of the phototherapeutic activities of ZnPcSmix in lung cancer cells included a 
change in cell morphology, a decrease in cell viability and proliferation, an increase in cytotoxicity and 
further cell damage evidence. Light-activated ZnPcSmix resulted in increased ROS production in both 
monolayer and multicellular tumor spheroid models of lung cancer [43,68]. The mechanisms of cell 
death were investigated post-irradiation in breast cancer using the same PC. The abundance of apoptotic 
cells, degradation of nuclear materials and the increase in the level of the expression of B-cell  
lymphoma-2, DNA fragmentation factor alpha and caspase-2 genes concurred with the validation of 
apoptosis as the induced mode of cell death [67]. 
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The effects of others PCs similar to ZnPcSmix, with the exception of the central atoms, were 
investigated in esophageal and breast cancer cells. Both AlPcSmix and GePcSmix were found to be 
effective at targeting these malignant cells and led to cytotoxicity in a dose-dependent manner.  
A relatively lower concentration of photoactivated AlPcSmix and GePcSmix showed greater apoptotic 
inducing capabilities [69]. The effects of SnPcSmix and SiPcSmix were used in esophageal cancer and 
compared to those of GePcSmix and two others PC mixes. All three metallated PCs led to better cancer 
damaging effects when compared to an unmetallated PC mix and binaphthalo-PC counterparts. 
GePcSmix caused and induced an inflammatory response and high intracellular ATP, which could have 
been an indication of a necrotic type of cell death [70]. 
2. Conclusions 
It can be concluded that programmed cell death improves the quality of life by eliminating undesirable 
cells from organisms. The execution of this process is accomplished by different mechanisms, including 
cell senescence, apoptosis, autophagy and necrosis. The induction of oxidative responses and the 
generation of ROS are essential for these eradicating mechanisms. PDT is an efficient means to target 
and induce damage in cancer cells and involves PSs, which can enhance both ROS production and cancer 
therapy. Metallated PCs are among the best currently-used PSs in vitro, and their use in clinical settings 
should be encouraged for prospective means of managing cancer. 
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